Abstract

Background: Patient and provider factors, including allopurinol medication adherence, affect gout treatment outcomes. Objectives: The aim of this study was to examine associations of patient and provider factors with optimal gout management. Methods: Linking longitudinal health and pharmacy dispensing records to questionnaire data, we assessed patient and provider factors among 612 patients with gout receiving allopurinol during a recent 1-year period. Associations of patient (medication adherence and patient activation) and provider factors (dose escalation, low-dose initiation, and anti-inflammatory prophylaxis) with serum urate (SU) goal achievement of less than 6.0 mg/dL were examined using multivariable logistic regression. Medication adherence was assessed as a mediator of these factors with goal achievement. Results: A majority of patients (63%) were adherent, whereas a minority received dose escalation (31%).Medication adherencewas associated with initiation of daily allopurinol doses of 100 mg/d or less (odds ratio [OR], 1.82; 95% confidence interval [CI], 1.20-2.76). In adjusted models, adherence (OR, 2.35; 95% CI, 1.50-3.68) and dose escalation (OR, 2.48; 95% CI, 2.48-4.25) were strongly associated with SU goal attainment. Low starting allopurinol dose was positively associated with SU goal attainment (OR, 1.11; 95% CI, 1.02-1.20) indirectly through early adherence, but also had a negative direct association with SU goal attainment (OR, 0.21; 95% CI, 0.12-0.37). Conclusions: Medication adherence and low starting dose combined with dose escalation represent promising targets for future gout quality improvement efforts. Low starting dose is associated with better SU goal attainment through increased medication adherence, but may be beneficial only in settings where appropriate dose escalation is implemented.

Original languageEnglish (US)
Pages (from-to)317-323
Number of pages7
JournalJournal of Clinical Rheumatology
Volume23
Issue number6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Allopurinol
Medication Adherence
Gout
Uric Acid
Odds Ratio
Confidence Intervals
Serum
Patient Participation
Patient Compliance
Quality Improvement
Anti-Inflammatory Agents
Logistic Models
Health

Keywords

  • Allopurinol
  • Gout
  • Outcomes
  • Patient activation
  • Uric acid

ASJC Scopus subject areas

  • Rheumatology

Cite this

Allopurinol medication adherence as a mediator of optimal outcomes in gout management. / Coburn, Brian W.; Bendlin, Kayli A.; Sayles, Harlan; Meza, Jane L; Russell, Cynthia L.; Mikuls, Ted R.

In: Journal of Clinical Rheumatology, Vol. 23, No. 6, 01.01.2017, p. 317-323.

Research output: Contribution to journalArticle

Coburn, Brian W. ; Bendlin, Kayli A. ; Sayles, Harlan ; Meza, Jane L ; Russell, Cynthia L. ; Mikuls, Ted R. / Allopurinol medication adherence as a mediator of optimal outcomes in gout management. In: Journal of Clinical Rheumatology. 2017 ; Vol. 23, No. 6. pp. 317-323.
@article{6ff6528fcd8040bead21630375cfdd2a,
title = "Allopurinol medication adherence as a mediator of optimal outcomes in gout management",
abstract = "Background: Patient and provider factors, including allopurinol medication adherence, affect gout treatment outcomes. Objectives: The aim of this study was to examine associations of patient and provider factors with optimal gout management. Methods: Linking longitudinal health and pharmacy dispensing records to questionnaire data, we assessed patient and provider factors among 612 patients with gout receiving allopurinol during a recent 1-year period. Associations of patient (medication adherence and patient activation) and provider factors (dose escalation, low-dose initiation, and anti-inflammatory prophylaxis) with serum urate (SU) goal achievement of less than 6.0 mg/dL were examined using multivariable logistic regression. Medication adherence was assessed as a mediator of these factors with goal achievement. Results: A majority of patients (63{\%}) were adherent, whereas a minority received dose escalation (31{\%}).Medication adherencewas associated with initiation of daily allopurinol doses of 100 mg/d or less (odds ratio [OR], 1.82; 95{\%} confidence interval [CI], 1.20-2.76). In adjusted models, adherence (OR, 2.35; 95{\%} CI, 1.50-3.68) and dose escalation (OR, 2.48; 95{\%} CI, 2.48-4.25) were strongly associated with SU goal attainment. Low starting allopurinol dose was positively associated with SU goal attainment (OR, 1.11; 95{\%} CI, 1.02-1.20) indirectly through early adherence, but also had a negative direct association with SU goal attainment (OR, 0.21; 95{\%} CI, 0.12-0.37). Conclusions: Medication adherence and low starting dose combined with dose escalation represent promising targets for future gout quality improvement efforts. Low starting dose is associated with better SU goal attainment through increased medication adherence, but may be beneficial only in settings where appropriate dose escalation is implemented.",
keywords = "Allopurinol, Gout, Outcomes, Patient activation, Uric acid",
author = "Coburn, {Brian W.} and Bendlin, {Kayli A.} and Harlan Sayles and Meza, {Jane L} and Russell, {Cynthia L.} and Mikuls, {Ted R}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/RHU.0000000000000561",
language = "English (US)",
volume = "23",
pages = "317--323",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Allopurinol medication adherence as a mediator of optimal outcomes in gout management

AU - Coburn, Brian W.

AU - Bendlin, Kayli A.

AU - Sayles, Harlan

AU - Meza, Jane L

AU - Russell, Cynthia L.

AU - Mikuls, Ted R

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Patient and provider factors, including allopurinol medication adherence, affect gout treatment outcomes. Objectives: The aim of this study was to examine associations of patient and provider factors with optimal gout management. Methods: Linking longitudinal health and pharmacy dispensing records to questionnaire data, we assessed patient and provider factors among 612 patients with gout receiving allopurinol during a recent 1-year period. Associations of patient (medication adherence and patient activation) and provider factors (dose escalation, low-dose initiation, and anti-inflammatory prophylaxis) with serum urate (SU) goal achievement of less than 6.0 mg/dL were examined using multivariable logistic regression. Medication adherence was assessed as a mediator of these factors with goal achievement. Results: A majority of patients (63%) were adherent, whereas a minority received dose escalation (31%).Medication adherencewas associated with initiation of daily allopurinol doses of 100 mg/d or less (odds ratio [OR], 1.82; 95% confidence interval [CI], 1.20-2.76). In adjusted models, adherence (OR, 2.35; 95% CI, 1.50-3.68) and dose escalation (OR, 2.48; 95% CI, 2.48-4.25) were strongly associated with SU goal attainment. Low starting allopurinol dose was positively associated with SU goal attainment (OR, 1.11; 95% CI, 1.02-1.20) indirectly through early adherence, but also had a negative direct association with SU goal attainment (OR, 0.21; 95% CI, 0.12-0.37). Conclusions: Medication adherence and low starting dose combined with dose escalation represent promising targets for future gout quality improvement efforts. Low starting dose is associated with better SU goal attainment through increased medication adherence, but may be beneficial only in settings where appropriate dose escalation is implemented.

AB - Background: Patient and provider factors, including allopurinol medication adherence, affect gout treatment outcomes. Objectives: The aim of this study was to examine associations of patient and provider factors with optimal gout management. Methods: Linking longitudinal health and pharmacy dispensing records to questionnaire data, we assessed patient and provider factors among 612 patients with gout receiving allopurinol during a recent 1-year period. Associations of patient (medication adherence and patient activation) and provider factors (dose escalation, low-dose initiation, and anti-inflammatory prophylaxis) with serum urate (SU) goal achievement of less than 6.0 mg/dL were examined using multivariable logistic regression. Medication adherence was assessed as a mediator of these factors with goal achievement. Results: A majority of patients (63%) were adherent, whereas a minority received dose escalation (31%).Medication adherencewas associated with initiation of daily allopurinol doses of 100 mg/d or less (odds ratio [OR], 1.82; 95% confidence interval [CI], 1.20-2.76). In adjusted models, adherence (OR, 2.35; 95% CI, 1.50-3.68) and dose escalation (OR, 2.48; 95% CI, 2.48-4.25) were strongly associated with SU goal attainment. Low starting allopurinol dose was positively associated with SU goal attainment (OR, 1.11; 95% CI, 1.02-1.20) indirectly through early adherence, but also had a negative direct association with SU goal attainment (OR, 0.21; 95% CI, 0.12-0.37). Conclusions: Medication adherence and low starting dose combined with dose escalation represent promising targets for future gout quality improvement efforts. Low starting dose is associated with better SU goal attainment through increased medication adherence, but may be beneficial only in settings where appropriate dose escalation is implemented.

KW - Allopurinol

KW - Gout

KW - Outcomes

KW - Patient activation

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=85045564981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045564981&partnerID=8YFLogxK

U2 - 10.1097/RHU.0000000000000561

DO - 10.1097/RHU.0000000000000561

M3 - Article

C2 - 28816767

AN - SCOPUS:85045564981

VL - 23

SP - 317

EP - 323

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 6

ER -